Exploring Diagnosis and Treatment of Non-Eosinophilic Chronic Rhinosinusitis

Monday, September 30, 2024

8:00 AM – 9:00 AM EDT

Location: MBCC, 230

CME/MOC Credit: 1

Disclosure(s):

Martin J. Citardi, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

William C. Yao, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Michael J. Marino, MD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Amber U. Luong, MD, PhD:

faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

PROGRAM DESCRIPTION: Over the past 5 years, chronic rhinosinusitis (CRS) treatment has been revolutionized by the introduction of biologics that target specific pathways of type 2 inflammation. While these type 2 inflammatory pathways are common in CRS, CRS itself is heterogenous syndrome of specific subtypes that share phenotypic features, but differ in underlying patho-etiologic mechanisms. In this panel presentation, we will explore those CRS subtypes that are not driven by type 2 inflammation. These CRS subtypes are often difficult to recognize, and their treatments, while well described in the literature, are not commonly discussed. In short, we will look for options for those patients with non-eosinophilic CRS who are failing initial treatments.
Specific CRS subtypes include odontogenic CRS, macrolide-responsive CRS, chronic infection and vasculitis. These CRS subtypes are encountered in the general ENT patient population, but often are diagnosed late. Thus, highlighting these CRS subtypes is important for all ENT physicians who treat nose and sinus conditions.
Specific cases will illustrate the relevant diagnostic clues for each condition, and then treatment options will be described. Panelists will discuss pragmatic tips that can be applied at the point-of-care. The case discussion will be supported through focused presentations of the published clinical reports and studies as well as consensus statements. The appropriate work-up, including laboratory testing and imaging, will be described. Innovative diagnostic modalities will be presented. In addition, a framework for approaching these CRS subtypes will be presented.

Learning Objectives:

Define difficult-to-treat, non-eosinophilic chronic rhinosinusitis (CRS).
Diagnose CRS subtypes, including odontogenic, macrolide-responsive, vasculitis and infection.
Select and monitor treatments for these CRS subtypes.

Moderator(s)

MC

Martin J. Citardi, MD

Department Chair and Vice Dean
McGovern Medical School (UTHealth Houston)
Bellaire, TX, United States

Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.

Panelist(s)

WY

William C. Yao, MD

Associate Professor
University of Texas Health Sciences Center at Houston
Houston, TX, United States

Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.
Michael J. Marino, MD

Associate Professor and Program Director, Department of Otolaryngology - Head & Neck Surgery
Mayo Clinic in Arizona
Phoenix, AZ, United States

Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.
AL

Amber U. Luong, MD, PhD

Professor of Otolaryngology, Vice Chair of Academic Affairs
University of Texas Houston, McGovern Medical School
Houston, TX, United States

Disclosure(s):
faculty for this accredited education activity has no relationship(s) with ineligible companies to disclose.